首页> 外文OA文献 >Legal and ethical considerations in processing patient‐identifiable data without patient consent: lessons learnt from developing a disease register
【2h】

Legal and ethical considerations in processing patient‐identifiable data without patient consent: lessons learnt from developing a disease register

机译:未经患者同意而处理患者可识别数据的法律和道德考虑:从开发疾病登记簿中学到的经验教训

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The legal requirements and justifications for collecting patient‐identifiable data without patient consent were examined. The impetus for this arose from legal and ethical issues raised during the development of a population‐based disease register. Numerous commentaries and case studies have been discussing the impact of the Data Protection Act 1998 (DPA1998) and Caldicott principles of good practice on the uses of personal data. But uncertainty still remains about the legal requirements for processing patient‐identifiable data without patient consent for research purposes. This is largely owing to ignorance, or misunderstandings of the implications of the common law duty of confidentiality and section 60 of the Health and Social Care Act 2001. The common law duty of confidentiality states that patient‐identifiable data should not be provided to third parties, regardless of compliance with the DPA1998. It is an obligation derived from case law, and is open to interpretation. Compliance with section 60 ensures that collection of patient‐identifiable data without patient consent is lawful despite the duty of confidentiality. Fears regarding the duty of confidentiality have resulted in a common misconception that section 60 must be complied with. Although this is not the case, section 60 support does provide the most secure basis in law for collecting such data. Using our own experience in developing a disease register as a backdrop, this article will clarify the procedures, risks and potential costs of applying for section 60 support.
机译:审查了未经患者同意收集患者可识别数据的法律要求和理由。其动力来自于建立基于人口的疾病登记册期间提出的法律和道德问题。许多评论和案例研究都在讨论1998年数据保护法(DPA1998)和Caldicott良好实践原则对个人数据使用的影响。但是,出于研究目的,未经患者同意而处理患者可识别数据的法律要求仍然存在不确定性。这在很大程度上是由于无知或对普通法保密义务和《 2001年健康与社会关怀法》第60条的含义的误解。普通法保密义务规定,不应将患者可识别的数据提供给第三方,无论是否符合DPA1998。这是源自判例法的义务,可以解释。尽管有保密义务,但遵守第60节可确保未经患者同意而收集患者可识别数据是合法的。对保密义务的恐惧导致了一个普遍的误解,即必须遵守第60条。虽然不是这种情况,但第60条支持的确为收集此类数据提供了法律上最安全的依据。本文将以我们在开发疾病登记册方面的经验为背景,阐明申请第60条支持的程序,风险和潜在成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号